News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Astellas Pharma Inc. Withdraws Japan Filing for Darexaban, Looks for Partners
February 16, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- Astellas Pharma has pulled its filing in Japan for its oral Factor Xa inhibitor darexaban after regulators said they needed to see more data.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Regulatory
Summit’s Potential Keytruda Rival Gets November FDA Decision Date
January 30, 2026
·
1 min read
·
Tristan Manalac
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
January 28, 2026
·
1 min read
·
Heather McKenzie
Legal
CytoDyn’s Former CEO Gets Jail Time, $5.3M+ Fine for Securities Fraud
January 27, 2026
·
2 min read
·
Tristan Manalac
Opinion
FDA Inspections Should Not Be Source of Stress
January 27, 2026
·
5 min read
·
Greg Walker
